- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01841580
Proteomic Profiles in Trabeculectomy Patients
Long-term Observation of Tear Proteomic Profiles and Ocular Surface in Trabeculectomy Patients Before and After Surgery
Approximately 70 million people world-wide are affected with glaucoma, of whom 6.7 million have bilateral blindness.5 Elevated intro-ocular pressure is the major modifiable risk factor in glaucoma, and reducing intraocular pressure to a consistently low level can delay disease progression and therefore, blindness.6 Topical intraocular pressure -lowering medication remains the first-line treatment for glaucoma, with surgical intervention playing a secondary role in cases suboptimally controlled with medication alone.
In this study, we plan to assess the change in tear proteins in trabeculectomy patients before and after operations. It is hoped that this study could help us gain more understanding of the possible mechanism accounting for the development of dry eye disease in glaucoma patients, which could help us develop better screening modalities and therapeutic agents for glaucoma patients at risk to prevent the development of dry eye disease.
Study Overview
Status
Conditions
Detailed Description
Study Objectives and Purpose
There are two primary aims in this study:
- To assess changes in the tear proteomic profiles in pre-trabeculectomy and post-trabeculectomy patients
- To assess the changes in clinical signs of the eye and tear film as well as dry eye symptoms.
Study Material Human Tears will be collected from patients in SNEC clinic
Study Design:
120 patients will be recruited for this study (details as described below). Schirmers I test, Tear Osmolarity, Tear Break Up Time (TBUT), Anterior segment optical coherence tomography (ASOCT) and Impression cytology will be done during the study visits. Subjective symptom and severity of dry eye disease will be assessed through Visual Analog Scale (VAS).
No. of visits:
There will be 4 visits in this study. Visit 1: Pre-trabeculectomy operation Visit 2: 6 month after trabeculectomy surgery Visit 3: 1 year after trabeculectomy surgery Visit 4: 3 years after trabeculectomy surgery
Selection and Withdrawal of Subjects Recruitment Criteria
- 120 patients will be recruited from glaucoma clinics in SNEC
- Patients age ≥ 21 years old
- Patients who require trabeculectomy operation
Treatment of subjects
Study Procedures:
- Fluorescein staining will be used to visualize patient eyes.
Schirmer's test will be used to measure the amount of tear production
- A small strip of filter paper will be inserted inside the lower eyelid
- A topical aneasthetic is placed into the eye before the filter paper to prevent tearing due to the irritation from the paper
- The eyes are closed for 5 minutes.
- The paper is then removed and the amount of moisture is measured
Impression cytology will be performed to collect the superficial conjunctival cells for analysis
- While the eye is still anaesthetized from Schirmer's test, one end of a filter paper will be impressed upon the temporal conjunctiva whilst the other hand is grasped in place with a blunt smooth edged forceps.
- The filter paper is removed from the conjunctiva with a peeling motion after 2-3 seconds.
- The paper is placed into an eppendorf tube for future analysis.
Tear osmolarity, Tear Break Up Time (TBUT) will be measured in all patients
a) Tear osmolarity will be measured using the osmolarity chip, 3 chips per eye
Anterior segment optical coherence tomography will be performed to assess the tear meniscus and image for any conjunctivochalasis
a) The patient will be asked to look at a target in the instrument while blinking normally. The instrument will scan the lower eyelid margin for imaging of the tear meniscus and conjunctivochalasis
- Symptoms and severity of dry eye disease will be assessed through the Visual Analog Scale (VAS) system
Assessment of efficacy Outcome Measures
- Symptoms and severity of dry eye disease will be quantified based on the Visual Analog Scale (VAS)11
- Amount of moisture of the filter paper will be measured in Schirmer's test
- Clinical assessment of dry eye disease through Tear break up time (TBUT) and Tear Osmolarity measurements
- Tear meniscus height and area in the images obtained with optical coherence tomography
Target sample size 120 subjects will be enrolled in the study.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 168751
- Singapore National Eye Centre/ Singapore Eye Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 120 patients will be recruited from glaucoma clinics in SNEC
- Patients age ≥ 21 years old
- Patients who require trabeculectomy operation
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline in the tear protein profiles in trabeculectomy patients at 3 years
Time Frame: Baseline and 3 years
|
Baseline and 3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Symptoms and severity of dry eye disease
Time Frame: Baseline and 3 years
|
Baseline and 3 years
|
|
Amount of tears will be measured
Time Frame: Baseline and 3 years
|
Baseline and 3 years
|
|
Tear Osmolarity will be measured
Time Frame: Baseline and 3 years
|
Baseline and 3 years
|
|
Tear meniscus height will be measured
Time Frame: Baseline and 3 years
|
Baseline and 3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R980/89/2012
- 2013/020/A (Other Identifier: Singhealth Centralised Institutional Review Board)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Hospices Civils de LyonRecruitingOpen-angle Glaucoma | Glaucoma Eye | Pigmentary Glaucoma | Closed-Angle Glaucoma | Pseudo Exfoliative SyndromeFrance
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Isfahan University of Medical SciencesActive, not recruitingAngle Closure Glaucoma | Glaucoma EyeIran
-
University of MiamiAbbVieRecruitingOcular Hypertension | Glaucoma | Open-Angle Glaucoma | Glaucoma SuspectUnited States
-
Ngoc Nguyen Inc.Alcon ResearchNot yet recruitingGlaucoma | Glaucoma, Open Angle | Open Angle Glaucoma (OAG) | Normal Tension Glaucoma (NTG)United States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Dr. Kaweh MansouriEnrolling by invitationGlaucoma, Angle-Closure | Surgery | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma; Drugs | Glaucoma, Pigmentary | Glaucoma Secondary | Glaucoma Open-Angle | Glaucoma Congenital | Glaucoma CapsulareSwitzerland
-
iSTAR MedicalInternational Drug Development InstituteActive, not recruitingGlaucoma, Open-Angle Glaucoma EyeIndia, Panama